Markers of insulin resistance in Polycystic ovary syndrome women: An update.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data
PubMed 35432749 · doi:10.4239/wjd.v13.i3.129
What was done
The authors conducted a narrative review synthesizing literature on insulin resistance (IR) in polycystic ovary syndrome (PCOS), evaluating existing and newly proposed surrogate diagnostic markers, and suggesting a classification system for clinical assessment.
What was found
The abstract reports that PCOS affects 5%-10% of women of reproductive age, and insulin resistance is present in 35%-80% of affected women. The hyperinsulinemic euglycemic glucose clamp is noted as the gold standard but is clinically impractical. Specific diagnostic accuracy metrics (e.g., sensitivity, specificity, or cut-offs) for the reviewed surrogate markers were not provided in the abstract.
Why it matters
Early identification of insulin resistance is critical to mitigating long-term cardiometabolic and reproductive risks in PCOS, yet routine clinical practice still lacks a universally accepted, highly accurate surrogate marker.
Limits
This is a narrative review with no systematic search criteria, quality appraisal of included studies, or quantitative pooling of marker performance reported in the abstract. Sample sizes and specifics of the evaluated studies are not provided.
Cited by
- supports Approximately 80% of individuals with PCOS have insulin resistance.